Our Sponsors
EU-PFF was founded on an ethos of collaboration and co-operation. We are proud to gratefully acknowledge the partnership, financial support and commitment to our patient community given by all of our sponsors.
Platinum Sponsor
has more than 100 years of heritage in respiratory disease across a range of respiratory conditions. They aim to go beyond slowing down disease progression and hope to one day discover a cure for these chronic, debilitating conditions.
Gold Sponsors
is researching multiple mechanisms and approaches, with the goal of helping those living with IPF and other forms of lung fibrosis.
Silver Sponsors
is dedicated to restoring organ function by developing therapies that modulate growth factors. With a focus on treating fibrosis, Agomab is advancing a pipeline of innovative treatments aimed at improving patients’ lives.
is focused on the development and commercialisation of an oral therapy for the treatment of chronic cough in IPF and other chronic cough conditions.
is certified as a B Corporation and is engaged in research collaborations to identify novel treatments for pulmonary fibrosis.
is certified as a B Corporation focussing on developing transformative therapies for severe and underserved conditions, particularly in pulmonary vascular and interstitial lung diseases, as well as neurological disorders.
is committed to working closely with the patient community and with scientific experts and clinicians to find innovative solutions that meet the needs of these patients.
is a clinical-stage biotech company developing inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. Their goal is to deliver inhaled formulations of effective medicines directly to lung tissue, thus potentially enhancing efficacy and avoiding side effects associated with systemic drug delivery.
Bronze Sponsors
is a global biopharma company dedicated to developing innovative medicines and vaccines that help people do more, feel better, and live longer. With a strong focus on respiratory diseases, GSK is committed to advancing research in pulmonary fibrosis and other serious conditions to improve patient outcomes.
is a clinical-stage biotech company developing transformative treatments for life-threatening diseases. They’re working on innovative therapies for conditions like idiopathic pulmonary fibrosis and various cancers, aiming to bring new hope to patients.
is a commercial stage innovator, committed to scientific excellence and dedicated to serving the patient community by delivering therapeutics that provide meaningful and differentiated clinical results and address urgent unmet need.
Want to support our cause?
We need your active help and participation in raising awareness of PF to shape healthcare policy, treatment, care and research in favour of Pulmonary Fibrosis patients in Europe and beyond.